UBS Maintains Neutral on RXO, Raises Price Target to $26
UBS analyst Thomas Wadewitz maintains RXO (NYSE: RXO ) with a Neutral and raises the price target from $22 to $26.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.